Transgene SA TRGNF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 477.10K | 318.90K | 159.80K | 98.80K | 37.90K |
| Total Other Revenue | 6.08M | 7.10M | 7.92M | 8.04M | 8.21M |
| Total Revenue | 6.56M | 7.42M | 8.08M | 8.14M | 8.25M |
| Cost of Revenue | 36.64M | 37.84M | 38.24M | 38.98M | 40.00M |
| Gross Profit | -30.08M | -30.42M | -30.16M | -30.84M | -31.75M |
| SG&A Expenses | 8.92M | 8.67M | 8.25M | 7.91M | 7.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 1.52M | 1.38M | 1.24M | 645.60K | 47.10K |
| Total Operating Expenses | 47.09M | 47.89M | 47.73M | 47.53M | 47.65M |
| Operating Income | -40.53M | -40.47M | -39.66M | -39.39M | -39.40M |
| Income Before Tax | -39.54M | -41.38M | -42.37M | -41.08M | -40.03M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -39.54 | -41.38 | -42.37 | -41.08 | -40.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.54M | -41.38M | -42.37M | -41.08M | -40.03M |
| EBIT | -40.53M | -40.47M | -39.66M | -39.39M | -39.40M |
| EBITDA | -38.95M | -38.91M | -38.14M | -37.91M | -37.94M |
| EPS Basic | -0.20 | -0.25 | -0.30 | -0.30 | -0.30 |
| Normalized Basic EPS | -0.13 | -0.16 | -0.18 | -0.19 | -0.19 |
| EPS Diluted | -0.21 | -0.26 | -0.30 | -0.30 | -0.31 |
| Normalized Diluted EPS | -0.13 | -0.16 | -0.18 | -0.19 | -0.19 |
| Average Basic Shares Outstanding | 861.85M | 719.99M | 578.13M | 553.95M | 529.78M |
| Average Diluted Shares Outstanding | 861.85M | 719.99M | 578.13M | 553.95M | 529.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |